📣 VC round data is live. Check it out!
- Public Comps
- Susmed
Susmed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Susmed and similar public comparables like Meditera, Meta Biomed, Xtant Medical, Theraclion and more.
Susmed Overview
About Susmed
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
Founded
2015
HQ

Employees
39
Website
Financials (LTM)
EV
$40M
Valuation Multiples
Start free trialSusmed Financials
Susmed reported last 12-month revenue of $3M.
In the same LTM period, Susmed generated had net loss of ($2M).
Revenue (LTM)
Susmed P&L
In the most recent fiscal year, Susmed reported revenue of $3M and EBITDA of ($2M).
Susmed is unprofitable as of last fiscal year, with gross margin of 90%, EBITDA margin of (59%), and net margin of (60%).
Financial data powered by Morningstar, Inc.
Susmed Stock Performance
Susmed has current market cap of $65M, and enterprise value of $40M.
Market Cap Evolution
Susmed's stock price is $3.83.
Susmed share price decreased by 11.6% in the last 30 days, and by 0.4% in the last year.
Susmed has an EPS (earnings per share) of $-0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40M | $65M | -3.5% | -11.6% | -36.9% | -0.4% | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSusmed Valuation Multiples
Susmed trades at 12.7x EV/Revenue multiple, and (21.8x) EV/EBITDA.
EV / Revenue (LTM)
Susmed Financial Valuation Multiples
As of June 3, 2026, Susmed has market cap of $65M and EV of $40M.
Susmed has a P/E ratio of (32.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Susmed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Susmed Margins & Growth Rates
In the most recent fiscal year, Susmed reported gross margin of 90%, EBITDA margin of (59%), and net margin of (60%).
Susmed Margins
Susmed Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Susmed Operational KPIs
Susmed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Susmed Competitors
Susmed competitors include Meditera, Meta Biomed, Xtant Medical, Theraclion, Osang Healthcare, SMAIO, Spectral AI, Austco Healthcare, Pangaea Oncology and Tobii.
Most Susmed public comparables operate across Healthcare Software, Medical Devices, B2B SaaS, Vertical SaaS, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.9x | - | 12.1x | - | |||
| 1.0x | - | 5.0x | - | |||
| 0.5x | 0.6x | 4.3x | 7.2x | |||
| 67.2x | - | (9.5x) | - | |||
| 0.8x | - | 9.2x | - | |||
| 5.8x | 5.1x | (60.2x) | (63.8x) | |||
| 3.3x | 3.3x | (14.1x) | - | |||
| 0.9x | 0.8x | 6.6x | 5.4x | |||
This data is available for Pro users. Sign up to see all Susmed competitors and their valuation data. Start Free Trial | ||||||
Susmed VC Funding History
Before going public, Susmed raised $7M in total equity funding, across 2 rounds.
Susmed Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Susmed
| When was Susmed founded? | Susmed was founded in 2015. |
| Where is Susmed headquartered? | Susmed is headquartered in Japan. |
| How many employees does Susmed have? | As of today, Susmed has over 39 employees. |
| Is Susmed publicly listed? | Yes, Susmed is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Susmed? | Susmed trades under 4263 ticker. |
| When did Susmed go public? | Susmed went public in 2021. |
| Who are competitors of Susmed? | Susmed main competitors include Meditera, Meta Biomed, Xtant Medical, Theraclion, Osang Healthcare, SMAIO, Spectral AI, Austco Healthcare, Pangaea Oncology, Tobii. |
| What is the current market cap of Susmed? | Susmed's current market cap is $65M. |
| What is the current revenue of Susmed? | Susmed's last 12 months revenue is $3M. |
| What is the current EV/Revenue multiple of Susmed? | Current revenue multiple of Susmed is 12.7x. |
| Is Susmed profitable? | No, Susmed is not profitable. |
| What is the current net income of Susmed? | Susmed's last 12 months net income is ($2M). |
| How many companies Susmed has acquired to date? | Susmed hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Susmed has invested to date? | Susmed hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Susmed
Lists including Susmed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.